1. Received in exchange for 3,294,998 shares of Common Stock of Ocera Subsidiary, Inc. (f/k/a Ocera Therapeutics, Inc.) in connection with the merger of Ocera Subsidiary, Inc. with a wholly owned subsidiary of Ocera Therapeutics, Inc. (f/k/a Tranzyme, Inc.), in which transaction Ocera Subsidiary, Inc. was the surviving corporation (the "Merger"). For each 1 share of Ocera Subsidiary, Inc.'s Common Stock, the reporting person was entitled to receive 0.11969414 shares of the Common Stock of Ocera Therapeutics, Inc. in the Merger. On the effective date of the Merger, the closing price of Ocera Therapeutics Inc.'s Common Stock was $5.70 per share.

2. The shares are held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX,LLC ("IMP9") the general partner of IW9, has sole voting and investment control over the shares held by IW9. The Reporting Person serves as a Venture Member of IMP9 and may be deemed to share voting and investment control with respect to the shares held by IW9. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of her respective pecuniary interest therein.

3. Received in exchange for 43,088 shares of Common Stock of Ocera Subsidiary, Inc. (f/k/a Ocera Therapeutics, Inc.) in connection with the Merger. For each 1 share of Ocera Subsidiary, Inc.'s Common Stock, the reporting person was entitled to receive 0.11969414 shares of the Common Stock of Ocera Therapeutics, Inc. in the Merger. On the effective date of the Merger, the closing price of Ocera Therapeutics Inc.'s Common Stock was $5.70 per share.

4. The option was immediately exercisable in full but any shares acquired upon exercise thereof were subject to restrictions on transfer. The option vested (and such transfer restrictions lapsed) as to 25% after one year from the vesting commencement date of August 14, 2008, and thereafter in monthly installments of 1/36th each.

5. Received in connection with the Merger in exchange for a stock option to acquire 100,000 shares of the common stock of Ocera Subsidiary, Inc. with an exercise price of $0.30 per share (without giving effect, in either case, to the exchange ratio in the Merger).

6. Includes shares issuable upon exercise of Ocera Subsidiary, Inc options granted to Linda S. Grais, M.D. ("Dr. Grais") while a Venture Member of IMP9 and prior to the Merger, which options are held for the economic benefit of IW9. IMP9 has sole voting and investment control over the shares held by IW9. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of her respective pecuniary interest therein.

7. The option was immediately exercisable in full but any shares acquired upon exercise thereof were subject to restrictions on transfer. The option vested (and such transfer restrictions lapsed) in monthly installments of 1/48th each, commencing January 1, 2009.

8. Received in connection with the Merger in exchange for a stock option to acquire 25,000 shares of the common stock of Ocera Subsidiary, Inc. with an exercise price of $0.22 per share (without giving effect, in either case, to the exchange ratio in the Merger).

9. The option was granted on February 11, 2010 with a vesting commencement date of January 1, 2010. The option is immediately exercisable in full but any shares acquired upon exercise thereof are subject to restrictions on transfer. The option vests (and transfer restrictions lapse) in monthly installments of 1/48th each, which installments commenced February 1, 2010.

/s/ Nina Kjellson

07/17/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v).